Search

Ankylosing Spondylitis Drugs Market

Ankylosing Spondylitis Drugs Market Size by Molecule Type (Small Molecules, Biologics, Biosimilars), Route of Administration (Parenteral, Oral), Distribution Channel, Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2021 to 2028

Base Year: 2020 Historical Data: 2018-19
  • Report ID: TBI-12527
  • Published Date: Oct, 2021
  • Pages: 218
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

Global ankylosing spondylitis drugs market is estimated to reach USD 9.82 billion by 2028, at a CAGR of 9.14% from 2021 to 2028. Global ankylosing spondylitis drugs market is witnessing a considerable growth owing to increasing incidences of ankylosing spondylitis across the globe.

Market Overview:

Ankylosing spondylitis (AS) is a form of ongoing joint inflammation which primarily affects the spine. It is rear type of arthritis inflammatory disease that, over the time, can cause some of the small bones spine (vertebrae) to fuse, which makes the spine less flexible and can result in a hunched-forward posture. Sometimes the inflammation can lead to form a new bone on the spine, which leads to the deformity, in more advanced cases. This condition is characterized by stiffness and back pain that typically appear in early adulthood or adolescence. It also affects the eyes, heart, lungs, and occasionally the kidneys. Over time, back movement regularly becomes restricted as the bones of the spine fuse together, which called an ankylosis. Males are getting affected two to three times more commonly than females.

Though the condition is not curable, exercise and medications can help in coping up with the ankylosing spondylitis condition. The main focus of the medication prescribed to a patient of AS is managing the pain and controlling the symptoms. The optimal treatment of ankylosing spondylitis consists of drugs that suppress immunity or reduce inflammation as well as physical therapy. There are a number of different classes and types of medications used in the treatment of ankylosing spondylitis. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin (Indocin, Tivorbex) and naproxen (Naprosyn) are the medications doctors most commonly used to treat ankylosingspondylitis. They help to relieve pain, inflammation, and stiffness. In addition to this, biologics are the newest type of treatment for ankylosing spondylitis. Furthermore, biosimilars also represent a safe alternative and an important new generation of drugs for the treatment of ankylosing spondylitis.

Get an overview of this study by requesting a free sample

Market Dynamics:

Drivers:
  • Increasing cases of female patients with ankylosing spondylitis

In the past years, men had a higher prevalence of ankylosing spondylitis than women and occurred more frequently in men than women (2:1). However, from the past few years, the male/female prevalence ratio has been decreased worldwide. This scenario is anticipated to positively influence the growth market over the forecast period. 

  • Rise in research and development expenditure

Increasing the research and development activities for the development of novel drugs to treat the ankylosing spondylitis is anticipated to propel the growth of the market in upcoming years. Many companies are heavily investing in and focusing on the development of unique drugs and new therapies. The pharmaceutical companies are also adopting the merger and acquisition strategies for the development and additional investment for the ankylosing spondylitis drugs. Thus, rising investment in the R&D to innovate new medicines is positively influencing the market growth. 

Restraints:
  • Limited awareness about the condition

Many patients do not seek medical help due to limited knowledge about ankylosing spondylitis in various countries. People avoided the pain and considered it as general back pain and neglect the symptoms. This scenario is most commonly observed in the developing countries, which results in limiting the growth of the market. 

Opportunities:
  • The emergence of biologics for the treatment of ankylosing spondylitis

Biologics are the newest type of treatment for ankylosing spondylitis, and it is genetically engineered from living organisms. Biologics works by blocking the protein, which is responsible for the inflammation in the ankylosing spondylitis. Many companies are working on the development of biologics for the treatment of ankylosing spondylitis, owing to its high effectiveness. Thus, rising use of biologics for ankylosing spondylitis is anticipated to offer the future growth opportunities for the pharmaceutical companies. 

Challenges:
  • Adverse side effects of medications 

Many patients experience some side effects associated with ankylosing spondylitis drugs, including nausea, vomiting, constipation, and drowsiness, stomach bleeding, gastric bleeding, heart attack, and stroke. Thus, various side effects of ankylosing spondylitis drugs hampering the growth of the market.

Segmentation Analysis:

The global ankylosing spondylitis drugs market has been segmented based on molecule type, route of administration, distribution channel, and regions.

  • The molecule type segment is divided into small molecules, biologics, and biosimilars. The biologics is anticipated to grow at the highest CAGR of 9.9% over the forecast period. This is attributable to its more promising results in clinical development as compared to other molecules. It helps to reduce the back pain and stiffness by targeting specific proteins in the immune system that cause inflammation, including tumour necrosis factor (TNF) and interleukin 17 (IL17). Besides, increasing focus of pharmaceutical companies to develop and launch more biologics drugs for the treatment of ankylosing spondylitis, further boosting the growth of the market. 
  • The route of administration segment includes oral and parental. The oral segment accounted for the significant market share of 64.8% in 2020. This is mainly due to, major drugs for these conditions given by oral route of administration. In addition to this, ease of administration and patient preference for oral medications, fueling the growth of this segment. 
  • The distribution channel segment includes hospitals, pharmacy, retail pharmacy, and online pharmacy. The hospital's pharmacy held the major market share and valued at USD 2.26 billion in 2020. This is attributed to a more extensive stock of medications, including more specialized and investigational medications for the treatment of ankylosing spondylitis. In addition to this, the rising incidence rate of the condition, elevation in the number of in-patient and out-patients, led to hospitalization, which is resulting in the growth of hospital pharmacy segment. However, online pharmacy segment is anticipated to grow at the highest CAGR of 10.2% over the forecast period. Increase in internet adoption across the globe and rising preference of patient for the online pharmacy due to convenience driving the growth of this segment. 
Regional Segmentation Analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and the Middle East and Africa. The North America region emerged as the largest market for the ankylosing spondylitis drugs market with a 40.6% share of the market revenue in 2020.

  • This is mainly attributed to the increasing incidence and higher prevalence of ankylosing spondylitis in countries such as the U.S. and Canada. Apart from this, high expenditure on healthcare and availability of advanced diagnostics tools, further boosting the growth of the market in the North America region. Furthermore, the presence of key pharmaceutical companies in the region, driving the growth of the market. 
  • Asia Pacific is an emerging region in the ankylosing spondylitis drugs market, owing to increasing awareness about ankylosing spondylitis disease in the region. Furthermore, increasing healthcare expenditure across the region, positively influencing the growth of the market in the region. 

The North America Ankylosing Spondylitis Drugs Market Share in 2020- 40.6%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

Competitive Analysis:

The key players are now concentrating on implementing strategies such as adopting new technology, product innovations, mergers & acquisitions, joint venture, alliances and partnerships to improve their market position in the global ankylosing spondylitis drugs industry.

In August 2017, BoehringerIngelheim Pharmaceuticals, Inc. announced FDA approval for Cyltezo(adalimumab-adbm), a biosimilar, for the treatment of multiple chronic inflammatory diseases including ankylosing spondylitis and rheumatoid arthritis. 

In December 2019, Amgen announced that The U.S. Food and Drug Administration (FDA) had approved Avsola (infliximab-axxq), a biosimilar to Remicade (infliximab), to treat active ankylosing spondylitis.

List of Key Market Players:

  • Merck & Co.
  • BoehringerIngelheim
  • UCBBiopharma
  • Amgen
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • Abbvie
  • Hetero
  • ZydusCadila
  • Izana Bioscience

Key Target Audience

  • Healthcare Institute
  • Drug Manufacture
  • Pharmaceutical Companies
  • Government Authorities and R&D Institutions
  • World Health Organization
  • Food and Drug Administration
  • Consulting And Research Firm

Report Description:

  • Global Ankylosing Spondylitis Drugs Market, Industry Analysis, Trends, Analysis and Forecast, 2021 to 2028 is a forthcoming/imminent research report which is to be published by The Brainy Insights.
  • 2020 is considered as the base year of the report. 2018 and 2019 are considered as the historic years and 2021 to 2028 are the forecast years. The global ankylosing spondylitis drugs market is based on revenue (USD Million/Billion). The report incorporates the market study on the basis of revenue and volume. The study covers the market share revenue/market share for each of the segments, regions and countries catering to global ankylosing spondylitis drugs market. The regions analyzed for the market are Europe, Asia Pacific, North America, South America and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
  • The report encompasses with the relative data & information, which have been validated by the leading industry professionals and experts all across the globe. The research report also delivers an outline of the attractiveness of ankylosing spondylitis drugs and regions which are deduced and formulated on the basis of their growth rate (CAGR), market size, and attractiveness by analyzing the present and future prospects to market growth and development in future.
  • The report illustrates the detailed (both quantitative and qualitative) analysis of historical data, revenues, key developments, along with the crucial strategies adopted by key organizations catering to global ankylosing spondylitis drugs market. This offers vital and in depth insights in order to depict the overall market scenario.
  • The report offers the detailed study for the company profiles of key organizations operating in the global ankylosing spondylitis drugs market and a comparative assessment based on their product offering, business overviews, geographic presence, business strategies, segment market share, product development &innovations, recent developments, joint venture, partnerships, mergers & acquisitions, strategic alliances, SWOT analysis, and key financial information. This helps in evaluating the overall competition present in the market scenario. 
  • The report provides an elaborative assessment of the porter’s five forces analysis coupled with SWOT analysis so as to provide business related data and information’s. Porter’s five forces model is analyzed to understand the overall competitive scenario that is prevailing in the market. Additionally, the SWOT analysis identifies both the positive and negative attributes of the market development which influences the company growth and development in order to sustain and survive in the long run.
  • Along with that, the report also focuses on the market related driving factors, growth limitations (restraints), potential industry opportunities, significant trends and development which act as a key potential for the investors. 
  • Potential growth prospects along with the penetration rate analysis of the products (market related i.e., global ankylosing spondylitis drugs market is covered in order to comprehend the adoption rate and evaluate the market size.

Frequesntly Asked Questions

As per The Brainy Insights, the size of the ankylosing spondylitis drugs market was valued at USD 4.93 billion in 2020 and is anticipated to reach USD 9.82 billion by 2028.

Global ankylosing spondylitis drugs market is growing at a CAGR of 9.14% during the forecast period 2021-2028.

The global ankylosing spondylitis drugs market has been segmented based on molecule type, route of administration, distribution channel, and regions. The oral segment accounted for the major market share in 2020.

The North America region emerged as the largest market for the ankylosing spondylitis drugs.

Increasing proportion of female patients with ankylosing spondylitis is the key driving factor for the ankylosing spondylitis drugs market.

Limited awareness about the condition may hamper the market growth.

Emergence of biologics for the treatment of ankylosing spondylitis will provide huge opportunities to the market.

Key players are Merck & Co., Boehringer Ingelheim, UCB Biopharma, Amgen, Janssen Biotech, Inc., Johnson & Johnson, Abbvie.

Get Your Report Customized

  • Further segmentation of the market on the basis of type, application, end use, product, technology, method, process and any other segment depending on the market
  • Segmentation on the basis of any specific country or region
  • Any segment can be classified on the basis of application
  • Application segment can be further divided on the basis of companies
  • The companies profiled are not limited, we can incorporate additional companies of your choice
  • We can split the company market share on the basis of product, application and region
  • Report can be prepared for any specific country/region/segment
  • Customers can be added on the basis of regions and countries
Request for Customization

1. Introduction
    1.1. Objectives of the Study
    1.2. Market Definition
    1.3. Research Scope
    1.4. Currency
    1.5. Key Target Audience

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
    4.1. Porter’s Five Forces Analysis
    4.2. Value Chain Analysis
    4.3. Top Investment Pockets
          4.3.1. Market Attractiveness Analysis By Molecule Type
          4.3.2. Market Attractiveness Analysis By Route of Administration
          4.3.3. Market Attractiveness Analysis By Distribution Channel
          4.3.4. Market Attractiveness Analysis By Region
    4.4. Industry Trends

5. Market Dynamics
    5.1. Market Evaluation
    5.2. Drivers
          5.2.1. Increasing proportion of female patients with ankylosing spondylitis
          5.2.2. Rise in research and development expenditure
    5.3. Restraints
          5.3.1. Limited awareness about the condition
    5.4. Opportunities
          5.4.1. Emergence of biologics for the treatment of ankylosing spondylitis
    5.5. Challenges
          5.5.1. Adverse side effects of medications

6. Global Ankylosing Spondylitis Drugs Market Analysis and Forecast, By Molecule Type
    6.1. Segment Overview
    6.2. Small Molecules
    6.3. Biologics
    6.4. Biosimilars

7. Global Ankylosing Spondylitis Drugs Market Analysis and Forecast, By Route of Administration
    7.1. Segment Overview
    7.2. Parenteral
    7.3. Oral

8. Global Ankylosing Spondylitis Drugs Market Analysis and Forecast, By Distribution Channel
    8.1. Segment Overview
    8.2. Hospitals Pharmacy
    8.3. Retail Pharmacy
    8.4. Online Pharmacy

9. Global Ankylosing Spondylitis Drugs MarketAnalysis and Forecast, By Regional Analysis
    9.1. Segment Overview
    9.2. North America
          9.2.1. U.S.
          9.2.2. Canada
          9.2.3. Mexico
    9.3. Europe
          9.3.1. Germany
          9.3.2. France
          9.3.3. U.K.
          9.3.4. Italy
          9.3.5. Spain
    9.4. Asia-Pacific
          9.4.1. Japan
          9.4.2. China
          9.4.3. India
    9.5. South America
          9.5.1. Brazil
    9.6. Middle East and Africa
          9.6.1. UAE
          9.6.2. South Africa

10. Global Ankylosing Spondylitis Drugs Market-Competitive Landscape
    10.1. Overview
    10.2. Market Share of Key Players in Global Ankylosing Spondylitis Drugs Market
          10.2.1. Global Company Market Share
          10.2.2. North America Company Market Share
          10.2.3. Europe Company Market Share
          10.2.4. APAC Company Market Share
    10.3. Competitive Situations and Trends
          10.3.1. Product Launches and Developments
          10.3.2. Partnerships, Collaborations, and Agreements
          10.3.3. Mergers & Acquisitions
          10.3.4. Expansions

11. Company Profiles
    11.1. Merck & Co.
          11.1.1. Business Overview
          11.1.2. Company Snapshot
          11.1.3. Company Market Share Analysis
          11.1.4. Company Product Portfolio
          11.1.5. Recent Developments
          11.1.6. SWOT Analysis
    11.2. Boehringer Ingelheim
          11.2.1. Business Overview
          11.2.2. Company Snapshot
          11.2.3. Company Market Share Analysis
          11.2.4. Company Product Portfolio
          11.2.5. Recent Developments
          11.2.6. SWOT Analysis
    11.3. UCB Biopharma
          11.3.1. Business Overview
          11.3.2. Company Snapshot
          11.3.3. Company Market Share Analysis
          11.3.4. Company Product Portfolio
          11.3.5. Recent Developments
          11.3.6. SWOT Analysis
    11.4. Amgen
          11.4.1. Business Overview
          11.4.2. Company Snapshot
          11.4.3. Company Market Share Analysis
          11.4.4. Company Product Portfolio
          11.4.5. Recent Developments
          11.4.6. SWOT Analysis
    11.5. Janssen Biotech, Inc.
          11.5.1. Business Overview
          11.5.2. Company Snapshot
          11.5.3. Company Market Share Analysis
          11.5.4. Company Product Portfolio
          11.5.5. Recent Developments
          11.5.6. SWOT Analysis
    11.6. Johnson & Johnson
          11.6.1. Business Overview
          11.6.2. Company Snapshot
          11.6.3. Company Market Share Analysis
          11.6.4. Company Product Portfolio
          11.6.5. Recent Developments
          11.6.6. SWOT Analysis
    11.7. Abbvie
          11.7.1. Business Overview
          11.7.2. Company Snapshot
          11.7.3. Company Market Share Analysis
          11.7.4. Company Product Portfolio
          11.7.5. Recent Developments
          11.7.6. SWOT Analysis
    11.8. Hetero
          11.8.1. Business Overview
          11.8.2. Company Snapshot
          11.8.3. Company Market Share Analysis
          11.8.4. Company Product Portfolio
          11.8.5. Recent Developments
          11.8.6. SWOT Analysis
    11.9. Zydus Cadila
          11.9.1. Business Overview
          11.9.2. Company Snapshot
          11.9.3. Company Market Share Analysis
          11.9.4. Company Product Portfolio
          11.9.5. Recent Developments
          11.9.6. SWOT Analysis
    11.10. Izana Bioscience
          11.10.1. Business Overview
          11.10.2. Company Snapshot
          11.10.3. Company Market Share Analysis
          11.10.4. Company Product Portfolio
          11.10.5. Recent Developments
          11.10.6. SWOT Analysis

List of Table

1. Global Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

2. Global Small Molecules Ankylosing Spondylitis Drugs Market, By Region, 2018–2028 (USD Billion)

3. Global Biologics Ankylosing Spondylitis Drugs Market, By Region, 2018–2028 (USD Billion)

4. Global Biosimilars Ankylosing Spondylitis DrugsMarket, By Region, 2018–2028 (USD Billion)

5. Global Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

6. Global Parenteral, Ankylosing Spondylitis Drugs Market, By Region, 2018–2028 (USD Billion)

7. Global Oral, Ankylosing Spondylitis Drugs Market, By Region, 2018–2028 (USD Billion)

8. Global Ankylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

9. Global Hospitals Pharmacy, Ankylosing Spondylitis Drugs Market, By Region, 2018–2028 (USD Billion)

10. Global Retail Pharmacy, Ankylosing Spondylitis Drugs Market, By Region, 2018–2028  (USD Billion)

11. Global Online Pharmacy, Ankylosing Spondylitis Drugs Market, By Region, 2018–2028 (USD Billion)

12. Global Ankylosing Spondylitis Drugs Market, By Region, 2018–2028 (USD Billion)

13. Global Ankylosing Spondylitis Drugs Market, By North America, 2018–2028 (USD Billion)

14. North America Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

15. North America Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

16. North America Ankylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

17. U.S. Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

18. U.S. Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

19. U.S.Ankylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

20. Canada Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

21. Canada Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

22. CanadaAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

23. Mexico Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

24. Mexico Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

25. MexicoAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

26. Europe Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

27. Europe Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

28. EuropeAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

29. Germany Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

30. Germany Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

31. GermanyAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

32. France Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

33. France Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

34. FranceAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

35. U.K. Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

36. U.K. Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

37. U.K.Ankylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

38. Italy Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

39. Italy Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

40. ItalyAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

41. Spain Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

42. Spain Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

43. SpainAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

44. Asia Pacific Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

45. Asia Pacific Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

46. Asia PacificAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

47. Japan Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

48. Japan Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

49. JapanAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

50. China Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

51. China Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

52. ChinaAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

53. India Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

54. India Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

55. IndiaAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

56. South America Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

57. South America Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

58. South America Ankylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

59. Brazil Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

60. Brazil Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

61. BrazilAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

62. Middle East and Africa Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

63. Middle East and Africa Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

64. Middle EastAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

65. UAE Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

66. UAE Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

67. UAEAnkylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

68. South Africa Ankylosing Spondylitis Drugs Market, By Molecule Type, 2018–2028 (USD Billion)

69. South Africa Ankylosing Spondylitis Drugs Market, By Route of Administration, 2018–2028 (USD Billion)

70. South Africa Ankylosing Spondylitis Drugs Market, By Distribution Channel, 2018–2028 (USD Billion)

List of Figures 

1. Global Ankylosing Spondylitis Drugs Market Segmentation

2. Ankylosing Spondylitis Drugs Market: Research Methodology

3. Market Size Estimation Methodology: Bottom-Up Approach

4. Market Size Estimation Methodology: Top-Down Approach

5. Data Triangulation

6. Porter’s Five Forces Analysis 

7. Value Chain Analysis 

8. Global Ankylosing Spondylitis Drugs Market Attractiveness Analysis By Molecule Type

9. Global Ankylosing Spondylitis Drugs Market Attractiveness Analysis By Route of Administration

10. Global Ankylosing Spondylitis Drugs Market Attractiveness Analysis By Distribution Channel

11. Global Ankylosing Spondylitis Drugs Market Attractiveness Analysis By Region

12. Global Ankylosing Spondylitis Drugs Market: Dynamics

13. Global Ankylosing Spondylitis Drugs Market Share By Molecule Type (2021 & 2028)

14. Global Ankylosing Spondylitis Drugs Market Share by Route of Administration (2021 & 2028)

15. Global Ankylosing Spondylitis Drugs Market Share by Distribution Channel (2021 & 2028)

16. Global Ankylosing Spondylitis Drugs Market Share by Regions (2021 & 2028)

17. Global Ankylosing Spondylitis Drugs Market Share by Company (2020)

This study forecasts revenue at global, regional, and country levels from 2018 to 2028. The Brainy Insights has segmented the global ankylosing spondylitis drugs market on the basis of below mentioned segments:

Global Ankylosing Spondylitis Drugs Market by Molecule Type:

  • Small Molecules
  • Biologics
  • Biosimilars

Global Ankylosing Spondylitis Drugs Market by Route of Administration:

  • Parenteral
  • Oral

Global Ankylosing Spondylitis Drugs Market by Distribution Channel:

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Global Ankylosing Spondylitis Drugs Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa         
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Ask for customization Request Sample Speak to analyst Inquire before buying

Flexible Purchase Options

  • Chapters of your choice
  • Quantitative Information for Historical & Forecasted Data
  • Regional/Country Level Reports
Request for Special Pricing

Get in touch with us

+1-315-215-1633

sales@thebrainyinsights.com

Our Clients

Why choose us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date